Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Breast Cancer Clinical Trial

— AMEERA-4  

Official title:

Phase 2 Window Study of Two Dose Levels of Amcenestrant [SAR439859] (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04191382
• Other study ID #: ACT16106
• Secondary ID: 2019-002015-26U1
• Status: Terminated
• Phase: Phase 2
• Start date: February 4, 2020
• Est. completion date: May 28, 2021

Study information

• Verified date: June 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective: To determine whether amcenestrant given at 2 different doses improved the antiproliferative activity when compared to letrozole. Secondary Objectives: - To assess the proportion of participants with a relative decrease from Baseline in percentage of positive tumor cells tested by immunohistochemistry greater than or equal to (>=) 50 percent (%) (Ki67 >=50%) in the three treatment arms. - To assess estrogen receptor (ER) degradation in biopsies in participants in the three treatment arms. - To assess safety in the three treatment arms.

Description:

Duration of the study, per participant, would include screening period of up to 14 days before randomization, treatment period of 14 days and post-treatment safety follow-up period of 30±7 days after last investigational medicinal product (IMP) intake.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 105
• Est. completion date: May 28, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

• Histological or cytological proven diagnosis of invasive breast adenocarcinoma.
• Localized breast cancer eligible for upfront breast conservative surgery or upfront mastectomy: Stage I, Stage II or operable Stage III (excluded T4) as defined in American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th edition 2017.
• Postmenopausal women as defined by one of the following:
• Spontaneous cessation of menses greater than (>) 12 months.
• or who had received hormonal replacement therapy but had discontinued the treatment and had follicle stimulating hormone (FSH) level in the postmenopausal range.
• or with status post bilateral surgical oophorectomy.
• or post bilateral ovarian ablation through pelvic radiotherapy.
• Breast tumor size of at least 10 millimeters (mm) in greatest dimension measured by ultrasound.
• Primary tumor had to be positive for Estrogen Receptors (ER+) and negative for HER2 (HER2-) receptor by immunohistochemistry.
• Ki67 level of at least 15% at diagnosis from immunohistochemistry of the tumor.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

Exclusion criteria:

• Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859 or letrozole.
• Participants unable to swallow normally and to take capsules or tablets.
• Participants with known active hepatitis A, B, C infection; or hepatic cirrhosis.
• Participant with any other cancer; adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant had been disease free for >3 years were allowed.
• Evidence of metastatic spread by standard assessment according to local practice.
• Treatment with strong Cytochrome P450 3A (CYP3A) inducers or drugs that had the potential to inhibit uridine diphosphate glucuronosyltransferase (UGT) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longest.
• Treatment with drugs that were sensitive substrates of P-glycoprotein (P-gp) or of breast cancer resistance protein (BCRP) within 2 weeks before first study treatment administration or 5 elimination half-lives whichever was longer.
• Use of any investigational agent within 4 weeks prior to randomization.
• Recent use of hormone replacement therapy (last dose less than or equal to [<=] 30 days prior to randomization).
• Prior anti-cancer treatment was not allowed unless it was then completed at least 1 year prior to inclusion into this trial.
• Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments).
• Inadequate hematological or renal function.
• Prothrombin time/international normalized ratio (INR) >1.5 * upper limit of normal (ULN) or outside therapeutic range if received anticoagulation that would have had affected the prothrombin time/INR.
• Any of the following abnormal liver function test results: Aspartate aminotransferase >1.5 * ULN; Alanine aminotransferase >1.5 * ULN; Total bilirubin >1.5 * ULN.
• Participants were employees of the clinical study site or other individuals directly involved in the conduct of the study, or immediate family members of such individuals.
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Amcenestrant (SAR439859)
Pharmaceutical form: Capsules, Route of administration: Oral
• Letrozole
Pharmaceutical form: Tablets, Route of administration: Oral

Locations

Country	Name	City	State
Belgium	Investigational Site Number 0560001	Leuven
Belgium	Investigational Site Number 0560002	Namur
France	Investigational Site Number 2500001	Nantes
France	Investigational Site Number 2500004	Paris
France	Investigational Site Number 2500002	Saint Cloud
France	Investigational Site Number 2500003	Toulouse Cedex 9
Italy	Investigational Site Number 3800004	Meldola
Italy	Investigational Site Number 3800001	Milano
Italy	Investigational Site Number 3800002	Milano
Japan	Investigational Site Number 3920002	Osaka-Shi
Japan	Investigational Site Number 3920003	Sapporo-Shi
Japan	Investigational Site Number 3920001	Yokohama-Shi
Puerto Rico	Investigational Site Number 8400007	Hato Rey
Russian Federation	Investigational Site Number 6430004	Moscow
Russian Federation	Investigational Site Number 6430006	Moscow
Russian Federation	Investigational Site Number 6430002	Saint -Petersburg
Russian Federation	Investigational Site Number 6430003	Saint-Petersburg
Russian Federation	Investigational Site Number 6430007	St.Petersburg
Spain	Investigational Site Number 7240005	Barcelona
Spain	Investigational Site Number 7240003	Córdoba
Spain	Investigational Site Number 7240001	Madrid
Spain	Investigational Site Number 7240002	Valencia / Valencia
Ukraine	Investigational Site Number 8040004	Kharkiv
Ukraine	Investigational Site Number 8040001	Uzhgorod
Ukraine	Investigational Site Number 8040002	Vinnytsia
Ukraine	Investigational Site Number 8040005	Zaporizhzhya
United States	Investigational Site Number 8400018	Fort Wayne	Indiana
United States	Investigational Site Number 8400005	Lincoln	Nebraska
United States	Investigational Site Number 8400010	Los Angeles	California
United States	Investigational Site Number 8400012	Tacoma	Washington
United States	Investigational Site Number 8400014	Tucson	Arizona
United States	Investigational Site Number 8400016	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Belgium,  France,  Italy,  Japan,  Puerto Rico,  Russian Federation,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline in Ki67 Level at Day 15	Tumor tissue collected through a core-cut biopsy at Baseline and Day 15 was used to determine Ki67 expression. Ki67 expression was defined as the percentage of positive tumor cells assessed by central reading. Ki67 percent change from Baseline for a given participant was defined as 100*(Ki67pre - Ki67post) / Ki67pre, where Ki67pre and Ki67post were pre-treatment and post-treatment Ki67 value of the participant. Adjusted geometric least square (LS) means and 95 percentage (%) confidence interval (CI) for the percent change were obtained from analysis of covariance (ANCOVA) model of the log proportional change i.e., log (Ki67post/ki67pre) with treatment and log-Ki67pre as fixed effect and converted by antilog transformation.	Baseline, Day 15
Secondary	Percentage of Participants With Percent Change From Baseline in Ki67 Greater Than or Equal to (>=) 50 Percent at Day 15	Tumor tissue collected through a core-cut biopsy at Baseline and Day 15 was used to determine Ki67 expression. Ki67 expression was defined as the percentage of positive tumor cells assessed by central reading. Ki67 percent change from Baseline for a given participant was defined as 100*(Ki67pre - Ki67post) / Ki67pre, where Ki67pre and Ki67post were pre-treatment and post-treatment Ki67 value of the participant.	Baseline, Day 15
Secondary	Change From Baseline in Estrogen Receptor (ER) Expression as Measured by H-Score at Day 15	Change from Baseline in ER expression was measured by H-Score. The H-score was calculated as the sum of the percent of cells staining positive (0 to 100) multiplied staining intensity level from 0 to 3 (0=none, 1=low, 2=moderate, 3=high). Total ER expression H-score ranged from 0 to 300, where higher score indicated stronger ER expression. Change from Baseline in H-Score equals H-scorepost minus H-scorepre; where H-scorepost and H-scorepre denoted post-treatment and pre-treatment H-scores, respectively. LS-means and 95% CI were obtained from an ANCOVA model for change from baseline with treatment and baseline as fixed effect.	Baseline, Day 15
Secondary	Number of Participants With Abnormalities: Hematological Parameters	Hematology parameters covered by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and included: Hemoglobin, Lymphocyte, Neutrophils, Leukocytes (white blood cells), Anemia, Platelets, Eosinophils, and international normalized ratio (INR). An NCI-CTCAE Grades 1 to 5 were described as: Grade 1-Mild; asymptomatic/mild symptoms; Grade 2-Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental daily activities. Grade 3-Severe/medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4-Life-threatening consequences; Grade 5-Death. Data for 'All Grades' were reported in this outcome measure.	From first dose of study drug up to Day 14
Secondary	Number of Participants With Abnormalities: Clinical Chemistry	Clinical chemistry laboratory parameters covered by NCI-CTCAE and included: Glucose, Potassium, Sodium, Creatinine. An NCI-CTCAE Grades 1 to 5 were described as: Grade 1-Mild; asymptomatic or mild symptoms; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental daily activities; Grade 3-Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; Grade 4-Life-threatening consequences; Grade 5-Death. Data for 'All Grades' were reported in this outcome measure.	From first dose of study drug up to Day 14